COMP <GO>
ATRA vs OKYO // GROSS PROFIT MARGIN
Atara Biotherapeutics Inc. (NASDAQ) VS. OKYO Pharma Limited (NASDAQ) • 15-METRIC TALLY: ATRA 1
— OKYO 1
■ METRIC PARITY
LAST: $8.01 (-6.10%) • MKT CAP: $85.6M
gross-margins
—
LAST: $1.47 (-2.00%) • MKT CAP: $78.7M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRA VS. OKYO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATRA | OKYO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 29.70% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 27.10% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -6.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.5 | 52.8 | -15.28 | OKYO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $85.6M | $78.7M | $6.9M | ATRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATRA REV | OKYO REV | ATRA GROSS % | OKYO GROSS % | ATRA FCF | OKYO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $120.8M | — | — | — | -$50.9M | — |
| FY 2024 | $128.9M | — | — | — | -$69.0M | — |
| FY 2023 | $8.6M | — | — | — | -$193.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRA // BETA —
OKYO // BETA —